GlaxoSmithKline fires back
Links shared publicly online about this topic.
- 1,355total visits
GlaxoSmithKline fires back
View full resource at theheart.org
Tags: Diabetes Type 2 Medication, Diabetes Medication, Avandia, Avandamet, Avandaryl, GlaxoSmithKline
Most Recently Shared on February 25, 2010 at 8:07 pm By:
GlaxoSmithKline fires back in defense of rosiglitazone: In its response, the company states it has been "proactive... http://bit.ly/a7G5Pk
Spring Fling Matchpoint Launch! Session Lineup AnnouncedHealth 2.0 News
health2news.com — “Today on the Health 2.0 Show we announced our lineup for the Launch! session in Boston on May 15th. Launch! is a series of rapid-fire, back-to-back, 3.5” View full resource at health2news.com
Most Recently Shared on May 1, 2012 at 7:18 pm By:
Health2.0 Conference Health Social Media
We've just announced our Spring Fling Launch! session lineup: http://t.co/CFZZiqbb via #health2con
Cub Scout Leader Fired For Being Gay! Fights Back!! | PerezHilton.com
perezhilton.com — “Jennifer Tyrell recently got the discriminatory boot after her local Cub Scout organization found out she was gay. In March, the Boy Scouts of America told Jennifer her sexual orientation...” View full resource at perezhilton.com
Most Recently Shared on April 26, 2012 at 7:30 pm By:
Change.org Health Organization
.@PerezHilton urges fans to sign Ohio mom's @Change petition to end anti- #gay discrimination in @BoyScouts http://t.co/ahDWEnI1
Coleman v. Court of Appeals of Maryland: A Warning to Women | RH Reality Check
rhrealitycheck.org — “Last week the U.S. Supreme Court held that states cannot be sued for denying workers sick leave. An employee of the Maryland state courts, Daniel Coleman, had sued for monetary damages after he was fired for requesting time off to take care of his health.” View full resource at rhrealitycheck.org
Most Recently Shared on March 26, 2012 at 4:45 pm By:
Coleman v. Court of Appeals of Maryland: A Warning to #Women. http://t.co/Cg1TuEFj #fem2 #p2 #tpot #healthcare #hcr #benefits
Santorum suggests Obama preferable to 'Etch-A-Sketch' Romney - latimes.com
latimes.com — “Rick Santorum 's latest attempt to use a Mitt Romney aide's "Etch-A-Sketch" remark against the Republican front-runner instead gave his rival a chance to fire back on Thursday, after Santorum seemed to say he'd rather see President Obama reelected than send Romney to the White House.” View full resource at latimes.com
Most Recently Shared on March 23, 2012 at 3:18 am By:
George Huba, Ph.D. Psychologist, PhD, and Doctor
Santorum suggests Obama preferable to 'Etch-A-Sketch' Romney - http://t.co/2iUoZm44 http://t.co/qWxByeg1
GSK, J&J back Index's new $200M fund for early-stage deals - FierceBiotech
fiercebiotech.com — “GlaxoSmithKline and Johnson & Johnson are teaming up with Index Ventures to launch a $200 million fund devoted exclusively to backing early-stage biotechs. And while its primary focus will be in Read more...” View full resource at fiercebiotech.com
Most Recently Shared on March 21, 2012 at 5:11 pm By:
Pete Shuster Promotional and Health Business Administrator
Good news for drug discovery: GSK, J&J back Index's new $200M fund for early-stage deals - FierceBiotech: http://t.co/5q1Vx6Mm via @AddThis
FDA panel backs Glaxo drug for rare cancer | ajc.com
ajc.com — “WASHINGTON — A panel of cancer experts rejected an experimental Merck drug for a rare form of cancer on Tuesday while recommending approval of a GlaxoSmithKline treatment for the same disease.” View full resource at ajc.com
Most Recently Shared on March 21, 2012 at 4:29 pm By:
Tom Heston, MD Doctor, Family Medicine Doctor, and Physician
FDA panel backs Glaxo drug for rare cancer - Atlanta Journal Constitution http://t.co/p4jwFZcO #medicine
FDA Backs Glaxo Drug For Rare Cancer | ThirdAge
thirdage.com — “ A panel of cancer experts rejected an experimental Merck drug for a rare form of cancer on Tuesday while recommending approval of a GlaxoSmithKline treatment for the same disease. Neither drug appears to help patients live longer, but panelists said Glaxo's Votrient helped delay tumor growth in the most vulnerable patients.” View full resource at thirdage.com
Most Recently Shared on March 21, 2012 at 12:19 am By:
FDA Backs Glaxo Drug For Rare Cancer http://t.co/QMfj2u64
FDA panel backs Glaxo drug for rare sarcoma cancer - Yahoo! News
news.yahoo.com — “From Yahoo! News: A panel of cancer experts rejected an experimental Merck drug for a rare form of cancer on Tuesday while recommending approval of a GlaxoSmithKline treatment for the same disease. Neither drug appears to help patients live longer, but panelists said Glaxo's Votrient helped delay tumor growth in the most vulnerable patients.” View full resource at news.yahoo.com
Most Recently Shared on March 20, 2012 at 6:57 pm By:
FDA panel backs Glaxo drug for rare sarcoma cancer: A panel of cancer experts voted against an experimental Merc... http://t.co/CS4hfxkn
FDA panel backs Glaxo drug for rare sarcoma cancer
medicalxpress.com — “(AP) -- A panel of cancer experts overwhelmingly backed the approval of a GlaxoSmithKline drug for a rare type of tumor, noting there are few other treatment options for patients.” View full resource at medicalxpress.com
Most Recently Shared on March 20, 2012 at 6:12 pm By:
PhysOrg Health News Health News
FDA panel backs Glaxo drug for rare sarcoma cancer http://t.co/bswyWkK2
FDA Panel Rejects Merck Drug for Sarcoma, but Backs Glaxo's Votrient - WSJ.com
online.wsj.com — “A federal advisory panel rejected an experimental Merck & Co. drug for use in patients with soft-tissue or bone sarcomas—on concerns that it didn't work well enough to offset potentially serious side effects—while backing a different drug from GlaxoSmithKline.” View full resource at online.wsj.com
Most Recently Shared on March 20, 2012 at 5:37 pm By:
FDA Panel Backs Glaxo Drug for Sarcoma http://t.co/Cc9B6D9P
FDA panel backs Glaxo drug for rare sarcoma cancer - Yahoo! News
news.yahoo.com — “From Yahoo! News: A panel of cancer experts rejected an experimental Merck drug for a rare form of cancer on Tuesday while recommending approval of a GlaxoSmithKline treatment for the same disease. Neither drug appears to help patients live longer, but panelists said Glaxo's Votrient helped delay tumor growth in the most vulnerable patients.” View full resource at news.yahoo.com
Most Recently Shared on March 20, 2012 at 5:29 pm By:
HealthTrendster Health Executive
FDA panel backs Glaxo drug for rare sarcoma cancer - A panel of cancer experts has backed the benefits of a GlaxoSmi... http://t.co/k7JJ13Oc
Zoo animals get Capital Grille meat - Boston.com
boston.com — “Zoo animals get Capital Grille meat - Boston.com” View full resource at boston.com
Most Recently Shared on March 16, 2012 at 5:40 pm By:
Maryn McKenna Health Communicator
these are great! RT @mattfeltz: Weekly aww: Back Bay fire a boon for hungry big cats at Southwick Zoo. http://t.co/ab9uOjJW
Manholes explode in Back Bay area - BostonHerald.com
bostonherald.com — “Three manholes on Huntington Avenue exploded today, sending flames shooting out of the steel covers as Nstar officials had just finished announcing all the power in the area had been restored — except to the Prudential Tower. Boston Fire Department spokesman Steve MacDonald said one manhole had...” View full resource at bostonherald.com
Most Recently Shared on March 16, 2012 at 3:30 pm By:
Greg Friese Health Professional
This is why I never walk or bike over a manhole. Manholes explode in Back Bay area - http://t.co/hYt7pzIA http://t.co/M4hLElBI
ICMCC News Page » Health Affairs I.T. Study Authors Fire Back at Mostashari
articles.icmcc.org — “ICMCC, International Council on Medical & Care Compunetics” View full resource at articles.icmcc.org
Most Recently Shared on March 15, 2012 at 7:00 pm By:
Health Affairs I.T. Study Authors Fire Back at Mostashari http://t.co/4MiBCviS #healthit #ehr
Researchers fire back on Mostashari for criticism of EHR study | Healthcare IT News
healthcareitnews.com — “Researchers fire back on Mostashari for criticism of EHR study | Healthcare IT News” View full resource at healthcareitnews.com
Most Recently Shared on March 14, 2012 at 7:40 pm By:
Researchers fire back on Mostashari for criticism of #EHR study | #Healthcare IT News from @DManos_IT_News http://t.co/GkyvVep9
Advertisement
